Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $56
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $54 to $56.
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $54 to $56.